CAR T therapy

UConn Health has announced the launch of a new CAR-T cell therapy program, bringing an advanced form of immunotherapy to its medical center in Connecticut. CAR-T treatment reengineers a patient's own immune cells to fight certain cancers, and the program is being promoted as a cutting-edge addition to the institution's clinical services.

Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.